Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

146 results about "Bone morphogenesis" patented technology

The process in which bones are generated and organized. [GOC:dph]

Soluble expression and purification method of recombinant human bone morphogenetic protein in prokaryotic system

PendingCN119120530ATo achieve full dissolutionBiologically activeBone-inducing factorMicroorganism based processesEscherichia coliCompetent cell
The invention discloses a soluble expression and purification method of recombinant human bone morphogenetic protein in a prokaryotic system. A gene sequence of a recombinant human bone morphogenetic protein (rhBMP) is spliced at the 3'terminal of a His-Linker-GB1 gene sequence, inserted into a prokaryotic expression system expression vector and transferred into a prokaryotic competent cell to be highly expressed in the cell in a soluble form, and finally, the expressed His-Linker-GB1-BMP fusion protein does not need to be subjected to inclusion body renaturation, so that the recombinant human bone morphogenetic protein (rhBMP) is obtained. The high-purity fusion protein can be obtained through one-step metal chelating chromatography (adsorption-elution mode), and the GB1 tag has small molecular weight and hardly affects the spatial structure and biological activity of rhBMP, so that the situation that an inclusion body is formed by expression of rhBMP in a traditional escherichia coli system and expression is performed in a structure-free and activity-free inclusion body form is avoided, and the expression efficiency is greatly improved. The method is simple and convenient to operate, is suitable for large-scale amplification, and has the characteristics of short period, high purity, stable process and the like.
Owner:JIANGNAN UNIV

Partially absorbable sports medicine orthopedic suture line and preparation method thereof

The invention relates to the field of biomedical textile materials, and discloses a partially absorbable sports medicine orthopedic suture line and a preparation method thereof.The suture line is prepared from, by mass, 50%-90% of polylactic acid and 10%-20% of polyglycolic acid. The mass content of polyglycolic acid is 10%-50%, the composite material further comprises a bioactive component, the mass content of the bioactive component is 0.1%-10%, the bioactive component comprises bone morphogenetic protein, silver nanoparticles and hydroxyapatite, the tensile strength of the suture line is 30-120 MPa, and under different physiological conditions, the suture line is not prone to fracture, and the suture line is not prone to fracture. And the degradation product can be compatible with surrounding tissues. The shape of the suture line can be automatically adjusted at the physiological temperature by embedding the shape memory alloy, and the suture line can adapt to dynamic changes of the tissue and provide uniform tension and support when interacting with the biological tissue due to the intelligent response capability, so that the tissue healing is effectively promoted.
Owner:周滢

CMyBPC marker combination for early discrimination of acute myocardial infarction type 2 and type 1

PendingCN118922721AMedical automated diagnosisDisease diagnosisESM1Lipid biomarker
The present invention relates to a method for assessing myocardial infarction, the method comprising the steps of: determining the amount of a first biomarker in a sample of a subject, the first biomarker being cMyBPC; determining an amount of a second biomarker in a sample of the subject, wherein the second biomarker is selected from the group consisting of BMP10 type peptide (bone morphogenetic protein type 10 peptide), FGF23 (fibroblast growth factor 23), BNP type peptide (brain natriuretic peptide type peptide), GDF-15 (growth differentiation factor 15), ANG2 (angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1) or such as cholesterol, LDL (low density lipoprotein) or APOAT (apolipoprotein A-1) a lipid biomarker; comparing the amount of biomarker to a reference for the biomarker and / or calculating a score for assessing myocardial infarction based on the amount of biomarker; and assessing the subject based on the comparison and / or calculation. The invention also relates to the use of a first biomarker, which is cMyBPC, and a second biomarker, which is selected from the group consisting of a BMP10 type peptide, FGF23, a BNP type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1 or a lipid biomarker such as cholesterol or LDL, for assessing myocardial infarction; or at least one detection agent for the first biomarker and at least one detection agent for the second biomarker. In addition, the invention further relates to a computer-implemented method for assessing myocardial infarction as well as a device and a kit for assessing myocardial infarction.
Owner:F HOFFMANN LA ROCHE & CO AG

Bone paste for repairing bone trauma and preparation method thereof

The invention relates to bone paste for repairing bone wounds and a preparation method of the bone paste, and belongs to the technical field of biomedical material manufacturing. The bone paste is prepared from nanoscale calcium-phosphorus biphase ceramic, biomimetic mineralized collagen fiber, biodegradable polymer, modified hyaluronic acid, beta-cyclodextrin coated recombinant human bone morphogenetic protein-7, an angiogenesis accelerant and an immunoregulation additive according to a certain proportion. The nano-scale calcium-phosphorus dual-phase ceramic is hydroxyapatite and beta-tricalcium phosphate dual-phase ceramic; the biomimetic mineralized collagenous fiber is prepared by mixing type I collagen freeze-dried fiber with hydroxypropyl chitosan and performing mineralization; the modified hyaluronic acid is hyaluronic acid-sulfydryl and hyaluronic acid-hydrazide; the angiogenesis accelerant is a polylactic acid sustained release microsphere loaded with tanshinone and hydroxyl polyethylene glycol biotin; the immunoregulation additive is disodium glycyrrhizinate, lentinan and astragalus polysaccharide. The bone paste can effectively improve the bone induction capacity, promote vascularization generation and reduce the immunogenicity risk.
Owner:HUBEI SHUANGXING PHARMA CO LTD

Soluble bone morphogenetic protein (BMP) receptor type-1b proteins and uses thereof

This application relates generally to the field of Bone Morphogenetic Protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for use in treating neurodegenerative diseases and / or demyelinating diseases.
Owner:LASK PHARMA INC

Bone defect repair material with activity and preparation method thereof

The invention discloses an active bone defect repair material and a preparation method thereof. The bone defect repair material is prepared by compounding collagen extracted from an animal source, a calcined bone matrix and bone morphogenetic protein composite microspheres and molding through a photocuring 3D printing technology. From the perspective of bionics, collagen is used as a framework material, a calcined bone matrix with low immunogenicity is used as a hard material to enhance mechanical support of the material, and bone morphogenetic protein composite microspheres have a synergistic effect, so that undifferentiated mesenchymal stem cells are guided to develop towards a specific direction in a long-acting manner. After the active bone defect repair material is implanted into a bone defect part, a microenvironment beneficial to cell adhesion and proliferation is provided for cells, and meanwhile, bone morphogenetic protein is slowly released and can act on the bone defect part for a long time, so that the differentiation and maturation process of osteoblasts is effectively promoted, and bone repair of the bone defect part is promoted.
Owner:ZHONGKEZHIGUANG BIOTECHNOLOGY (HEBEI PROVINCE) CO LTD

Microcapsule and preparation method thereof, self-repairing resin and preparation method thereof, and dental prosthesis

The invention provides a microcapsule and a preparation method thereof, self-repairing resin and a preparation method thereof, and a dental prosthesis. The microcapsule is prepared from the following raw materials: a polymer matrix, an active substance, a plasticizer, a dispersing agent and metacrylic acid esters, wherein the active substance contains bone morphogenetic protein; the self-repairing resin comprises the microcapsule; the dental restoration comprises the microcapsule and / or self-repairing resin. According to the invention, the problem that the dental resin material has micro-cracks and wear in the long-term service process is solved.
Owner:LIAONING UPCERA CO LTD

4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

This document relates to methods and materials for using 4-aminopyridine (4-AP) and / or one or more derivatives of 4-AP. For example, a composition containing 4-AP and / or one or more derivatives of 4-AP can be administered (e.g., orally administered) to a mammal to increase a level of bone morphogenetic protein 2 (BMP-2) polypeptides within the mammal. For example, a composition containing 4-AP and / or one or more derivatives of 4-AP can be administered (e.g., orally administered) to a mammal having bone loss to increase the level of BMP-2 within the mammal, thereby treating the mammal's bone loss.
Owner:THE PENN STATE RES FOUND INC

A bone trauma repair bone paste and its preparation method

The present invention relates to a bone trauma repair bone paste and a preparation method thereof, belonging to the technical field of biomedical material manufacturing. The bone paste of the present invention is prepared by mixing nano calcium phosphate biphasic ceramics, biomimetic mineralized collagen fibers, biodegradable polymers, modified hyaluronic acid, β-cyclodextrin-coated recombinant human bone morphogenetic protein-7, angiogenesis promoters and immunomodulatory additives in a certain proportion; the nano calcium phosphate biphasic ceramics are hydroxyapatite and β-tricalcium phosphate biphasic ceramics; the biomimetic mineralized collagen fibers are prepared by mineralizing freeze-dried fibers of type I collagen admixed with hydroxypropyl chitosan; the modified hyaluronic acid is hyaluronic acid-thiol and hyaluronic acid-hydrazide; the angiogenesis promoter is a polylactic acid sustained-release microsphere loaded with tanshinone and hydroxy polyethylene glycol biotin; the immunomodulatory additive is disodium glycyrrhizinate, lentinan and astragalus polysaccharide. The bone paste can effectively improve the bone induction ability, promote angiogenesis and reduce the risk of immunogenicity.
Owner:HUBEI SHUANGXING PHARMA CO LTD

Skin regeneration and repair method based on stem cells

PendingCN119015511Amaintain stable functionalitygrow fastProsthesisBlood vesselAmino acid
The invention discloses a skin regeneration and repair method based on stem cells, which is characterized in that the stable function of the stem cells is maintained by optimizing the culture conditions and culture medium formula of the stem cells and selecting proper cell sources and types, and the adaptability and effectiveness of the stem cells are ensured by regularly performing function evaluation and quality control. Epidermal growth factors, fibroblast growth factors, bone morphogenetic proteins, serum, serum-free substitutes, amino acids, vitamins and other culture medium components are selectively added according to different types of stem cells, and through the optimization measures, the stable function of the stem cells can be effectively maintained; the reliability and the effect in research and clinical application are improved; meanwhile, after the skin wound surface of the patient is subjected to sterile treatment, growth factors for promoting angiogenesis are added to the surface of the wound surface, so that the transplanted skin and the wound surface can be more adapted and compatible, and the wound surface skin is helped to grow quickly.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI +1

Compound based on DNA tetrahedron and preparation method and application thereof

The invention provides a DNA tetrahedron-based compound as well as a preparation method and application thereof, and belongs to the field of medicines. The invention designs a bioactive composite hydrogel scaffold modified by a functionalized DNA tetrahedron compound containing BMP-2, and the functionalized BMP-2 binding peptide is stably combined with a tetrahedron framework structure with a unique three-dimensional space structure and fine programmability in a chemical click mode. And further preparing with methacrylated hyaluronic acid to obtain the composite hydrogel stent. The functional DNA tetrahedron compound can efficiently capture BMP-2, the composite hydrogel scaffold can capture endogenous BMP-2 in a targeting manner in the early stage of bone defect and stimulate stem cell osteogenic differentiation so as to promote in-situ osteogenesis, a series of complications caused by delivery of exogenous bone morphogenetic protein-2 are avoided, the in-vivo stability is poor, and the in-vivo bone morphogenetic protein-2 can be used for preparing the bone morphogenetic engineering scaffold. The method has the advantages of high safety, high cost and the like, and has a good application prospect.
Owner:SICHUAN UNIV

Method for producing platelet quality control product by using iPS (induced pluripotent stem) cells and platelet quality control product

The invention relates to the technical field of biology, in particular to a method for producing a platelet quality control product by using iPS cells and the platelet quality control product, and the method comprises the following steps: controlling overexpression of a specific gene in the iPS cells by using a gene editing technology to obtain an iPS cell line containing the specific iPS cells; a differentiation procedure is started by adding a culture medium containing a tetracycline derivative, and meanwhile, a fibroblast growth factor 2 and a bone morphogenetic protein 4 are added to promote mesoderm differentiation; growth factors and tetracycline derivatives are added to induce overexpression of specific gene segments and promote formation of specific megakaryocytes; adding an AhR antagonist and a ROCK inhibitor into the recovered specific megakaryocyte, and culturing to obtain platelets; and screening a platelet standard substance based on platelet functions and preparing the platelet standard substance into a quality control substance.
Owner:BLUE OCEAN TIANYUAN BIOTECHNOLOGY (BEIJING) CO LTD

Culture method of bone marrow mesenchymal stem cells

The invention belongs to the technical field of stem cell culture, and discloses a culture method of bone marrow mesenchymal stem cells. A culture medium added with glutathione, L-ascorbic acid, L-glutamine, human serum albumin, sodium hydrosulfide, insulin, insulin-like growth factor-1, deer bone morphogenetic protein and antler stem cell exosome extract is used for culturing the bone marrow mesenchymal stem cells, and osteogenic differentiation of the bone marrow mesenchymal stem cells can be directionally induced. The culture medium does not contain animal serum, the formula is simple, the components are controllable, the cultured bone marrow mesenchymal stem cells are high in activity and good in state, the expression of marker genes of osteogenic differentiation is up-regulated, the regulation and control efficiency and accuracy of osteogenic differentiation are remarkably improved, and sufficient cell sources are provided for scientific research and clinic.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY

Pharmaceutical composition for preventing or treating metabolic diseases containing bone morphogenetic protein 10 as an active ingredient

The present invention relates to a composition for preventing or treating metabolic diseases, which contains bone morphogenetic protein 10 (BMP10) as an active ingredient. It has been confirmed that BMP10-treated mouse embryonic mesenchymal cell line C3H10T1 / T2 cells promoted brown fat differentiation, and increased brown fat differentiation of stromal vascular fraction adipose stem cells isolated from subcutaneous adipose tissue. It has also been confirmed that BMP10-treated animal models of obesity induced weight loss, improved insulin resistance, and changes in blood lipid levels resulted. Therefore, the composition containing BMP10 as an active ingredient can be used as a preventive or therapeutic agent for metabolic diseases, including obesity, diabetes, and dyslipidemia.
Owner:GIL MEDICAL CENT

Bone repair material as well as preparation method and application thereof

The invention discloses a bone repair material as well as a preparation method and application thereof. The bone repair material is prepared from recombinant human collagen, recombinant human bone morphogenetic protein 2 and hydroxyapatite, wherein the ratio of the inorganic matter to the organic matter in the bone repair material is (64-66): (36-34). The bone repair material disclosed by the invention takes the recombinant human collagen as a core raw material, so that the components and the structure of the prepared material are ensured to be highly consistent with those of natural bone tissues; secondly, by adding the recombinant human bone morphogenetic protein 2, the osteogenic activity of the material is further enhanced. The finally obtained recombinant human collagen active bone repair material completely retains the triple helix structure of the recombinant human collagen, so that the recombinant human collagen active bone repair material has complete biological activity, and also has the outstanding advantages of good osteogenic activity, no disease and virus transmission risk and no immunogenicity.
Owner:JHM BIOPHARMACEUTICAL (HANGZHOU) CO LTD

Tropnin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction

PendingUS20250362308A1Disease diagnosisBiological testingCardiac myosinCardiac infarction
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Culture medium system for pluripotency maintenance and directional induction of embryonic stem cells and application of culture medium system

The invention relates to the technical field of biology, and discloses a culture medium system for pluripotency maintenance and directional induction of embryonic stem cells and application of the culture medium system. 0.5 to 0.8 part of tetramethylenediamine; 0.2 to 0.5 part of corpus luteum hormone; 1-2 parts of a vitamin mixture; 2-4 parts of bovine serum albumin; 0.5 to 1.0 part of sodium bicarbonate; 0.2 to 0.4 part of an antibiotic mixed solution; 1 to 2 parts of biotin; 0.5 to 1.0 part of bone morphogenetic protein; and 0.1 to 0.2 part of magnesium ethylene diamine tetraacetate. A multi-factor regulation and control system is constructed, signal inhibition, a three-dimensional scaffold and a metabolic regulation module are combined, pluripotency of the embryonic stem cells is stably maintained, culture uniformity, structural support and differentiation resistance are remarkably improved, and the technical bottleneck of a traditional system in the aspects of induction efficiency and stability is broken through.
Owner:BEIJING HEALTH & BIOTECH (H&B) CO LTD

BMP1 and PD-1 combined inhibition immunotherapy

Methods of improving PD-1 based immunotherapy in a subject suffering from a solid cancer, comprising decreasing bone morphogenetic protein 1 (BMP1) levels or function in T cells or in a tumor microenvironment (TME) or extracellular matrix (ECM) of the solid cancer are provided. Methods of treating a solid cancer comprising administering a PD-1 based immunotherapy and decreasing BMP1 levels or function in T cells or a TME or ECM of the solid cancer are also provided. Antibody drug conjugates comprising an anti-PDl blocking antibody and a BMP1 inhibiting small molecule or antibody or antigen binding fragment thereof small molecule inhibitor and pharmaceutical compositions for use in the methods of the invention are also provided.
Owner:TECHNION RES & DEV FOUND LTD

A DNA tetrahedron-based complex, and a preparation method and use thereof

The application provides a DNA tetrahedron-based complex and a preparation method and application thereof, and belongs to the field of medicines. The application designs a functionalized DNA tetrahedron complex modified bioactive composite hydrogel scaffold containing BMP-2, combines the functionalized BMP-2 binding peptide with the tetrahedron framework structure with unique three-dimensional spatial structure and fine programmability through a chemical clicking mode, and further prepares the composite hydrogel scaffold by combining with methacrylated hyaluronic acid. The functionalized DNA tetrahedron complex realizes the performance of efficiently capturing BMP-2, and the composite hydrogel scaffold realizes the targeted capture of endogenous BMP-2 in the early stage of bone defect and stimulates the osteogenic differentiation of stem cells to promote in-situ osteogenesis, avoids a series of complications caused by the delivery of exogenous bone morphogenetic protein-2, and solves the problems of poor in-vivo stability, safety and high cost, and has a good application prospect.
Owner:SICHUAN UNIV

A wear-resistant polymer material and preparation method thereof

ActiveCN118562280BPolymer sciencePlant fibre
The present invention provides a wear-resistant polymer material and a preparation method thereof, wherein the wear-resistant polymer material comprises the following raw materials in parts by weight: 30-50 parts of polyurethane resin, 5-15 parts of nanocellulose, 10-20 parts of plant fiber, 20-40 parts of mineral powder, 5-10 parts of plasticizer, 5-10 parts of filler, 3-5 parts of lubricant, and 3-5 parts of mineralizer, wherein the mineralizer comprises bone morphogenetic protein, mineralization inducing polypeptide, and ethylenediaminetetraacetic acid. The mineralizer improves the friction performance and mechanical properties of the polymer material by inducing the mineralization of the polymer material. The bone morphogenetic protein induces the mineral components in the mineral powder to form an ordered structure in the polymer material, and the mineralization inducing polypeptide can promote the orderly arrangement and deposition of the mineral powder in the polymer material matrix, thereby forming a more tough and wear-resistant structure. At the same time, ethylenediaminetetraacetic acid induces the polymer material to form a mineral phase with a specific structure and morphology through complexation with metal ions, thereby further optimizing the performance of the polymer material.
Owner:GUANGDONG ENZINIER SPECIAL PLASTICS CO LTD

Bioinductive collagen anchor for tissue repair

A suture anchor includes an implanted portion configured to insert within an opening formed in bone of a patient and exposed portion configured to remain exposed. One or more sutures are laced through at least the implanted portion and possibly the exposed portion. Once tensioned, the suture causes the implanted portion to wedge within the opening and resist removal. The exposed portion may be placed over and / or around tissue and the suture may be passed through the tissue and knotted to secure the tissue to the suture anchor. The implanted portion may be infused with bone growth factors and the exposed portion may be infused with healing factors, such as Bone Morphogenic Protein-2 (BMP-2) and Platelet Rich Plasma (PRP).
Owner:MCKAY ROBERT TRENT

BMP-2 recombinant protein, coding gene and prokaryotic expression method thereof

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.
Owner:YEASEN BIOTECHNOLOGY (SHANGHAI) CO LTD

Method of generating hemangioblasts

A method of differentiating pluripotent stem cells into hemangioblasts comprising incubating the pluripotent stem cells in a first serum-free differentiation medium comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to induce differentiation of the pluripotent stem cells into hemangioblasts or hemangioblast-containing embryoid bodies is provided. The hemangioblasts or embryoid bodies may be cultured in a second differentiation medium comprising at least granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin-3 (IL-3) for a period of time sufficient to generate alveolar-like macrophages.
Owner:HOSPITAL FOR SICK CHILDREN

Antagonists

The present invention relates to bone morphogenetic protein 6 (BMP6) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
Owner:KYMBA LIMITED

Compositions of extracellular vesicles and method using the same

A composition comprising primed extracellular vesicles and a biologically or pharmaceutically acceptable carrier, wherein the primed extracellular vesicles comprise an upregulated miRNA, and a fold change of the upregulated miRNA of the primed extracellular vesicles compared to miRNA of naturally occurring extracellular vesicles is greater than 1. A method for preventing, treating, or ameliorating a bone defect or a dental defect comprising administering the composition to a subject in need thereof. A method for producing the composition, comprising: cultivating a stem cell in a culture medium containing a Polygonum multiflorum Thunb extract and at least one selected from the group consisting of baicalin and bone morphogenetic protein 6 to obtain a cell culture.
Owner:ASCENSION MEDICAL BIOTECHNOLOGY CO LTD

Oral cavity restoration membrane for guiding tissue regeneration and preparation method thereof

The invention relates to the technical field of oral medical materials, in particular to a tissue regeneration-guided oral repair membrane and a preparation method thereof. Comprising an outer layer and an inner layer, wherein the outer layer is a porous scaffold layer formed by a degradable polymer A, and the polymer A is selected from at least one of polylactic acid, polyglycolic acid, polycaprolactone or a copolymer thereof; the inner layer is loaded with a biocompatible hydrogel layer of a bioactive factor, and the bioactive factor is selected from bone morphogenetic protein, platelet-derived growth factor, vascular endothelial growth factor or a combination thereof. Comprising the following steps: preparing an outer layer solution; forming an outer-layer stent; preparing an inner layer precursor solution; gradient compounding and interface construction; performing crosslinking and curing; and post-processing. The invention provides a novel repairing film with intelligent degradation adaptability and precise biological factor controlled release capability.
Owner:CHANGZHOU NO 2 PEOPLES HOSPITAL

FCA-BExo composite material as well as preparation method and application thereof

The invention relates to the technical field of biomedical materials, in particular to an fCA-BExo composite material and a preparation method and application thereof. According to the complex, the cobalt-aluminum double hydroxide nanosheets are synthesized, mesenchymal stem cells are induced to secrete exosomes rich in bone morphogenetic proteins, fCA-BExo is formed, and the multiple effects of resisting oxidation, removing ROS, inhibiting inflammatory response and promoting osteogenic differentiation are achieved. The layered structure and surface electron vacancies of the nanosheet bring excellent ROS removal performance and biocompatibility, the exosome synergistically optimizes targeting and osteogenic induction effect, and the bone marrow microenvironment can be significantly improved. The complex can be efficiently dispersed in PBS or normal saline, is applied to osteoporosis diagnosis and treatment, and has the advantages of simplicity and convenience in operation, safety, high efficiency and transformation potential.
Owner:XUZHOU MEDICAL UNIVERSITY +1

SiRNA of targeted bone morphogenetic protein 2, modified siRNA and application of siRNA

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.
Owner:PEKING UNIV +1